Abdul Hannan Siddiqui, Fizzah Batool, Shayan Khan, Syed Shabbeer Rizvi, Saad Usman, Huzaifa Jawed, Muhammad Hammad Ali, Tatheer Zehra, Abdul Rafay Adil, Masifah Anwar, Areeba Hanif, Saad Khalid Hassan, Mark William Noble, Abdul Moeed, Salim Surani
{"title":"碳酸氢钠治疗慢性肾病代谢性酸中毒的安全性和有效性：一项系统综述和荟萃分析","authors":"Abdul Hannan Siddiqui, Fizzah Batool, Shayan Khan, Syed Shabbeer Rizvi, Saad Usman, Huzaifa Jawed, Muhammad Hammad Ali, Tatheer Zehra, Abdul Rafay Adil, Masifah Anwar, Areeba Hanif, Saad Khalid Hassan, Mark William Noble, Abdul Moeed, Salim Surani","doi":"10.5527/wjn.v14.i1.101078","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Kidney dysfunction and reduced filtration capacity due to chronic kidney disease (CKD) lead to a shift in the body's acid-base balance, ultimately causing metabolic acidosis (MA). Sodium bicarbonate has been used as a supplement to alleviate the symptoms and reverse the acidosis, and it may even slow the progression of CKD. However, its safety profile and overall effectiveness are uncertain.</p><p><strong>Aim: </strong>To conduct a systematic review and meta-analysis of clinical trials assessing sodium bicarbonate's safety and efficacy for treating CKD-induced MA.</p><p><strong>Methods: </strong>Medline, Scopus, EMBASE, and Cochrane Central were systematically searched from inception until May 2024 to select all relevant randomized control trials (RCTs) and non-RCT (NRCTs) evaluating the effectiveness of sodium bicarbonate in correcting MA in end-stage renal disease patients. In addition, ClinicalTrials.gov, Medrxiv.org, and Google Scholar were searched for other literature. A random-effects meta-analysis was performed to derive mean differences (MD) and risk ratios (RR) with their 95%CI for continuous and dichotomous outcomes respectively.</p><p><strong>Results: </strong>Following a systematic search of the databases, 20 RCTs and 2 and NRCTs comprising 2932 patients were included in our study. The results revealed that sodium bicarbonate significantly increased serum bicarbonate in CKD patients (MD: 2.59, 95%CI: 0.95-4.22; <i>P</i> = 0.02; <i>I</i> <sup>2</sup> = 95%). However, there was a non-significant increase in estimated glomerular filtration rate (eGFR) in patients on sodium bicarbonate therapy (MD: 0.93, 95%CI: -1.88-3.75; <i>P</i> = 0.52; <i>I</i> <sup>2</sup> = 93%). Upon assessment of the safety profile of sodium bicarbonate, no significant association was found in the outcomes of death/prolonged hospitalization (RR: 1.05, 95%CI: 0.84-1.32; <i>P</i> = 0.66; <i>I</i> <sup>2</sup> = 0%), or gastrointestinal disorders (RR: 1.64, 95%CI: 0.35-7.66; <i>P</i> = 0.53; <i>I</i> <sup>2</sup> = 76%), or worsening edema (RR: 1.26, 95%CI: 0.94-1.68; <i>P</i> = 0.12; <i>I</i> <sup>2</sup> = 37%) when compared to control.</p><p><strong>Conclusion: </strong>Sodium bicarbonate therapy may halt worsening kidney function by correcting serum bicarbonate levels and treating MA. Although sodium bicarbonate does not significantly improve the eGFR, it may potentially prevent CKD progression while maintaining an overall favorable safety profile.</p>","PeriodicalId":94272,"journal":{"name":"World journal of nephrology","volume":"14 1","pages":"101078"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755234/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safety and efficacy of sodium bicarbonate for treating metabolic acidosis in chronic kidney disease: A systematic review and meta-analysis.\",\"authors\":\"Abdul Hannan Siddiqui, Fizzah Batool, Shayan Khan, Syed Shabbeer Rizvi, Saad Usman, Huzaifa Jawed, Muhammad Hammad Ali, Tatheer Zehra, Abdul Rafay Adil, Masifah Anwar, Areeba Hanif, Saad Khalid Hassan, Mark William Noble, Abdul Moeed, Salim Surani\",\"doi\":\"10.5527/wjn.v14.i1.101078\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Kidney dysfunction and reduced filtration capacity due to chronic kidney disease (CKD) lead to a shift in the body's acid-base balance, ultimately causing metabolic acidosis (MA). Sodium bicarbonate has been used as a supplement to alleviate the symptoms and reverse the acidosis, and it may even slow the progression of CKD. However, its safety profile and overall effectiveness are uncertain.</p><p><strong>Aim: </strong>To conduct a systematic review and meta-analysis of clinical trials assessing sodium bicarbonate's safety and efficacy for treating CKD-induced MA.</p><p><strong>Methods: </strong>Medline, Scopus, EMBASE, and Cochrane Central were systematically searched from inception until May 2024 to select all relevant randomized control trials (RCTs) and non-RCT (NRCTs) evaluating the effectiveness of sodium bicarbonate in correcting MA in end-stage renal disease patients. In addition, ClinicalTrials.gov, Medrxiv.org, and Google Scholar were searched for other literature. A random-effects meta-analysis was performed to derive mean differences (MD) and risk ratios (RR) with their 95%CI for continuous and dichotomous outcomes respectively.</p><p><strong>Results: </strong>Following a systematic search of the databases, 20 RCTs and 2 and NRCTs comprising 2932 patients were included in our study. The results revealed that sodium bicarbonate significantly increased serum bicarbonate in CKD patients (MD: 2.59, 95%CI: 0.95-4.22; <i>P</i> = 0.02; <i>I</i> <sup>2</sup> = 95%). However, there was a non-significant increase in estimated glomerular filtration rate (eGFR) in patients on sodium bicarbonate therapy (MD: 0.93, 95%CI: -1.88-3.75; <i>P</i> = 0.52; <i>I</i> <sup>2</sup> = 93%). Upon assessment of the safety profile of sodium bicarbonate, no significant association was found in the outcomes of death/prolonged hospitalization (RR: 1.05, 95%CI: 0.84-1.32; <i>P</i> = 0.66; <i>I</i> <sup>2</sup> = 0%), or gastrointestinal disorders (RR: 1.64, 95%CI: 0.35-7.66; <i>P</i> = 0.53; <i>I</i> <sup>2</sup> = 76%), or worsening edema (RR: 1.26, 95%CI: 0.94-1.68; <i>P</i> = 0.12; <i>I</i> <sup>2</sup> = 37%) when compared to control.</p><p><strong>Conclusion: </strong>Sodium bicarbonate therapy may halt worsening kidney function by correcting serum bicarbonate levels and treating MA. Although sodium bicarbonate does not significantly improve the eGFR, it may potentially prevent CKD progression while maintaining an overall favorable safety profile.</p>\",\"PeriodicalId\":94272,\"journal\":{\"name\":\"World journal of nephrology\",\"volume\":\"14 1\",\"pages\":\"101078\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755234/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5527/wjn.v14.i1.101078\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5527/wjn.v14.i1.101078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Safety and efficacy of sodium bicarbonate for treating metabolic acidosis in chronic kidney disease: A systematic review and meta-analysis.
Background: Kidney dysfunction and reduced filtration capacity due to chronic kidney disease (CKD) lead to a shift in the body's acid-base balance, ultimately causing metabolic acidosis (MA). Sodium bicarbonate has been used as a supplement to alleviate the symptoms and reverse the acidosis, and it may even slow the progression of CKD. However, its safety profile and overall effectiveness are uncertain.
Aim: To conduct a systematic review and meta-analysis of clinical trials assessing sodium bicarbonate's safety and efficacy for treating CKD-induced MA.
Methods: Medline, Scopus, EMBASE, and Cochrane Central were systematically searched from inception until May 2024 to select all relevant randomized control trials (RCTs) and non-RCT (NRCTs) evaluating the effectiveness of sodium bicarbonate in correcting MA in end-stage renal disease patients. In addition, ClinicalTrials.gov, Medrxiv.org, and Google Scholar were searched for other literature. A random-effects meta-analysis was performed to derive mean differences (MD) and risk ratios (RR) with their 95%CI for continuous and dichotomous outcomes respectively.
Results: Following a systematic search of the databases, 20 RCTs and 2 and NRCTs comprising 2932 patients were included in our study. The results revealed that sodium bicarbonate significantly increased serum bicarbonate in CKD patients (MD: 2.59, 95%CI: 0.95-4.22; P = 0.02; I2 = 95%). However, there was a non-significant increase in estimated glomerular filtration rate (eGFR) in patients on sodium bicarbonate therapy (MD: 0.93, 95%CI: -1.88-3.75; P = 0.52; I2 = 93%). Upon assessment of the safety profile of sodium bicarbonate, no significant association was found in the outcomes of death/prolonged hospitalization (RR: 1.05, 95%CI: 0.84-1.32; P = 0.66; I2 = 0%), or gastrointestinal disorders (RR: 1.64, 95%CI: 0.35-7.66; P = 0.53; I2 = 76%), or worsening edema (RR: 1.26, 95%CI: 0.94-1.68; P = 0.12; I2 = 37%) when compared to control.
Conclusion: Sodium bicarbonate therapy may halt worsening kidney function by correcting serum bicarbonate levels and treating MA. Although sodium bicarbonate does not significantly improve the eGFR, it may potentially prevent CKD progression while maintaining an overall favorable safety profile.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
